Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease, Physiological Reviews, vol.90, issue.3, pp.905-981, 2010. ,
DOI : 10.1152/physrev.00041.2009
Symptomatic treatment of Huntington disease, Neurotherapeutics, vol.1, issue.7848, pp.181-197, 2008. ,
DOI : 10.1016/j.nurt.2008.01.008
Mutant Huntingtin Promotes the Fibrillogenesis of Wild-type Huntingtin: A POTENTIAL MECHANISM FOR LOSS OF HUNTINGTIN FUNCTION IN HUNTINGTON'S DISEASE, Journal of Biological Chemistry, vol.278, issue.42, pp.41452-41461, 2003. ,
DOI : 10.1074/jbc.M303354200
Identities of Sequestered Proteins in Aggregates from Cells with Induced Polyglutamine Expression, The Journal of Cell Biology, vol.16, issue.2, pp.283-294, 2001. ,
DOI : 10.1146/annurev.neuro.23.1.217
Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis, Proceedings of the National Academy of Sciences, vol.99, issue.14, pp.999310-9315, 2002. ,
DOI : 10.1073/pnas.152101299
Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease, Proceedings of the National Academy of Sciences, vol.101, issue.9, pp.3224-3229, 2004. ,
DOI : 10.1073/pnas.0400243101
The ubiquitin-proteasome pathway in Huntington's disease, Sci World J, vol.8, pp.421-433, 2008. ,
A Huntingtin Peptide Inhibits PolyQ-Huntingtin Associated Defects, PLoS ONE, vol.24, issue.7, p.68775, 2013. ,
DOI : 10.1371/journal.pone.0068775.s009
Mutant huntingtin-impaired degradation of ??-catenin causes neurotoxicity in Huntington's disease, The EMBO Journal, vol.80, issue.14, pp.2433-2445, 2010. ,
DOI : 10.1038/ng1219
Early alterations of autophagy in Huntington disease-like mice, Autophagy, vol.6, issue.8, pp.1206-1208, 2010. ,
DOI : 10.4161/auto.6.8.13617
The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis, Human Molecular Genetics, vol.16, issue.1, pp.61-77, 2007. ,
DOI : 10.1093/hmg/ddl440
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease, Journal of Neuroscience, vol.29, issue.43, pp.13589-13602, 2009. ,
DOI : 10.1523/JNEUROSCI.4286-09.2009
Oligonucleotide therapeutic approaches for Huntington disease, Journal of Clinical Investigation, vol.121, issue.2, pp.500-507, 2011. ,
DOI : 10.1172/JCI45130
A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse, Proceedings of the National Academy of Sciences, vol.104, issue.42, pp.16685-16689, 2007. ,
DOI : 10.1073/pnas.0707842104
Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice, Neuroscience Letters, vol.449, issue.2, pp.87-92, 2009. ,
DOI : 10.1016/j.neulet.2008.06.015
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice, Nat Genet, vol.26, issue.3, pp.300-306, 2000. ,
Wild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In Vivo, The American Journal of Human Genetics, vol.68, issue.2, pp.313-324, 2001. ,
DOI : 10.1086/318207
Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course, Brain, vol.126, issue.4, pp.946-955, 2003. ,
DOI : 10.1093/brain/awg077
Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules, Cell, vol.118, issue.1, pp.127-138, 2004. ,
DOI : 10.1016/j.cell.2004.06.018
Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease, BMC Neuroscience, vol.7, issue.1, p.80, 2006. ,
DOI : 10.1186/1471-2202-7-80
Normal huntingtin function: an alternative approach to Huntington's disease, Nature Reviews Neuroscience, vol.217, issue.12, pp.919-930, 2005. ,
DOI : 10.1038/nrn1806
Protective role of Engrailed in a Drosophila model of Huntington's disease, Human Molecular Genetics, vol.17, issue.22, pp.3601-3616, 2008. ,
DOI : 10.1093/hmg/ddn255
Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice, Cell, vol.87, issue.3, pp.493-506, 1996. ,
DOI : 10.1016/S0092-8674(00)81369-0
Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/2 Mouse Model of HD, PLoS ONE, vol.20, issue.7, p.60012, 2013. ,
DOI : 10.1371/journal.pone.0060012.s015
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation, J Neurosci, vol.19, issue.8, pp.3248-3257, 1999. ,
Protein transduction technology, Current Opinion in Biotechnology, vol.13, issue.1, pp.52-56, 2002. ,
DOI : 10.1016/S0958-1669(02)00284-7
Transduction peptides: from technology to physiology, Nature Cell Biology, vol.6, issue.3, pp.189-196, 2004. ,
DOI : 10.1038/ncb0304-189
Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer, Advanced Drug Delivery Reviews, vol.57, issue.4, pp.579-596, 2005. ,
DOI : 10.1016/j.addr.2004.10.005
Phase behavior of reverse microemulsions based on Peceol??, Journal of Colloid and Interface Science, vol.416, pp.139-146, 2014. ,
DOI : 10.1016/j.jcis.2013.10.058
URL : https://hal.archives-ouvertes.fr/hal-00926026
NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease, Neurobiology of Disease, vol.48, issue.3, pp.282-289, 2012. ,
DOI : 10.1016/j.nbd.2012.06.026
SH3GL3 Associates with the Huntingtin Exon 1 Protein and Promotes the Formation of Polygln-Containing Protein Aggregates, Molecular Cell, vol.2, issue.4, pp.427-436, 1998. ,
DOI : 10.1016/S1097-2765(00)80142-2
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease, Nature Medicine, vol.10, issue.2, pp.148-154, 2004. ,
DOI : 10.1038/nm985
Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation, Neurobiology of Disease, vol.39, issue.3, pp.423-438, 2010. ,
DOI : 10.1016/j.nbd.2010.05.014
Oral biodrug delivery using cell-penetrating peptide, Advanced Drug Delivery Reviews, vol.64, issue.6, pp.531-539, 2012. ,
DOI : 10.1016/j.addr.2011.12.014
The MTT Tetrazolium Salt Assay Scrutinized: How to Use this Assay Reliably to Measure Metabolie Activity of Cell Cultures in vitro for the Assessment of Growth Characteristics, IC50-Values and Cell Survival, Clinical Chemistry and Laboratory Medicine, vol.33, issue.11, pp.813-823, 1995. ,
DOI : 10.1515/cclm.1995.33.11.813
Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues, Journal of Pharmacological and Toxicological Methods, vol.55, issue.3, pp.279-288, 2007. ,
DOI : 10.1016/j.vascn.2006.11.004
Huntington's disease: The current state of research with peripheral tissues, Experimental Neurology, vol.219, issue.2, pp.385-397, 2009. ,
DOI : 10.1016/j.expneurol.2009.05.012
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease, J Neurosci, vol.22, issue.5, pp.1592-1599, 2002. ,
Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes, Journal of Cell Science, vol.126, issue.16, pp.3678-3685, 2013. ,
DOI : 10.1242/jcs.126086
URL : https://hal.archives-ouvertes.fr/pasteur-00874692
The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation, Nature Structural & Molecular Biology, vol.11, issue.12, pp.1279-1285, 2009. ,
DOI : 10.1074/jbc.M205809200
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease, Cell, vol.101, issue.1, pp.57-66, 2000. ,
DOI : 10.1016/S0092-8674(00)80623-6
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature, vol.19, issue.7010, pp.805-810, 2004. ,
DOI : 10.1016/j.nbd.2004.04.001
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data, The Lancet Neurology, vol.12, issue.7, pp.637-649, 2013. ,
DOI : 10.1016/S1474-4422(13)70088-7
Cardiac dysfunction in the R6/2 mouse model of Huntington???s disease, Neurobiology of Disease, vol.25, issue.2, pp.297-308, 2007. ,
DOI : 10.1016/j.nbd.2006.09.016
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis, Neuron, vol.74, issue.6, pp.1031-1044, 2012. ,
DOI : 10.1016/j.neuron.2012.05.009
Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening, Journal of Biological Chemistry, vol.275, issue.14, pp.10437-10442, 2000. ,
DOI : 10.1074/jbc.275.14.10437
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo, Proceedings of the National Academy of Sciences, vol.102, issue.3, pp.892-897, 2005. ,
DOI : 10.1073/pnas.0408936102
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies, Proceedings of the National Academy of Sciences, vol.102, issue.32, pp.11563-11568, 2005. ,
DOI : 10.1073/pnas.0505321102
Intrabodies Binding the Proline-Rich Domains of Mutant Huntingtin Increase Its Turnover and Reduce Neurotoxicity, Journal of Neuroscience, vol.28, issue.36, pp.9013-9020, 2008. ,
DOI : 10.1523/JNEUROSCI.2747-08.2008
Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein, Nature Biotechnology, vol.257, issue.3, pp.256-263, 2010. ,
DOI : 10.1038/nbt.1608
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins, Progress in Neurobiology, vol.97, issue.2, pp.190-204, 2012. ,
DOI : 10.1016/j.pneurobio.2011.11.004
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908675